Lung_NNP
cancer_NN
is_VBZ
a_DT
disease_NN
of_IN
uncontrolled_JJ
cell_NN
growth_NN
in_IN
tissues_NNS
of_IN
the_DT
lung_NN
._.

This_DT
growth_NN
may_MD
lead_VB
to_TO
metastasis_NNS
,_,
invasion_NN
of_IN
adjacent_JJ
tissue_NN
and_CC
infiltration_NN
beyond_IN
the_DT
lungs_NNS
._.

The_DT
vast_JJ
majority_NN
of_IN
primary_JJ
lung_NN
cancers_NNS
are_VBP
carcinomas_NNS
of_IN
the_DT
lung_NN
,_,
derived_VBN
from_IN
epithelial_JJ
cells_NNS
._.

Lung_NNP
cancer_NN
,_,
the_DT
most_RBS
common_JJ
cause_NN
of_IN
cancer-related_JJ
death_NN
in_IN
men_NNS
and_CC
the_DT
second_NN
most_RBS
common_JJ
in_IN
women_NNS
,_,
is_VBZ
responsible_JJ
for_IN
worldwideannually_NN
._.

The_DT
most_RBS
common_JJ
symptoms_NNS
are_VBP
shortness_NNS
of_IN
breath_NN
,_,
coughing_NNP
-LRB-_-LRB-
including_VBG
coughing_VBG
up_RP
blood_NN
-RRB-_-RRB-
,_,
and_CC
weight_NN
loss_NN
._.

The_DT
main_JJ
types_NNS
of_IN
lung_NN
cancer_NN
are_VBP
small_JJ
cell_NN
lung_NN
carcinoma_NN
and_CC
non-small_JJ
cell_NN
lung_NN
carcinoma_NN
._.

This_DT
distinction_NN
is_VBZ
important_JJ
because_IN
the_DT
treatment_NN
varies_VBZ
;_:
non-small_JJ
cell_NN
lung_NN
carcinoma_NN
-LRB-_-LRB-
NSCLC_NNP
-RRB-_-RRB-
is_VBZ
sometimes_RB
treated_VBN
with_IN
surgery_NN
,_,
while_IN
small_JJ
cell_NN
lung_NN
carcinoma_NN
-LRB-_-LRB-
SCLC_NNP
-RRB-_-RRB-
usually_RB
responds_VBZ
better_RBR
to_TO
chemotherapy_NN
and_CC
radiation_NN
._.

The_DT
most_RBS
common_JJ
cause_NN
of_IN
lung_NN
cancer_NN
is_VBZ
long_JJ
term_NN
exposure_NN
to_TO
tobacco_NN
smoke_NN
._.

The_DT
occurrence_NN
of_IN
lung_NN
cancer_NN
in_IN
non-smokers_NNS
,_,
who_WP
account_VBP
for_IN
fewer_JJR
than_IN
10_CD
%_NN
of_IN
cases_NNS
,_,
appears_VBZ
to_TO
be_VB
due_JJ
to_TO
a_DT
combination_NN
of_IN
genetic_JJ
factors_NNS
,_,
radon_NN
gas_NN
,_,
asbestos_NN
,_,
and_CC
air_NN
pollution_NN
,_,
including_VBG
second-hand_JJ
smoke_NN
._.

Lung_NNP
cancer_NN
may_MD
be_VB
seen_VBN
on_IN
chest_NN
x-ray_JJ
and_CC
computed_JJ
tomography_NN
-LRB-_-LRB-
CT_NNP
scan_NNP
-RRB-_-RRB-
._.

The_DT
diagnosis_NN
is_VBZ
confirmed_VBN
with_IN
a_DT
biopsy_NN
._.

This_DT
is_VBZ
usually_RB
performed_VBN
via_IN
bronchoscopy_JJ
or_CC
CT-guided_JJ
biopsy_NN
._.

Treatment_NNP
and_CC
prognosis_NNP
depend_VBP
upon_IN
the_DT
histological_JJ
type_NN
of_IN
cancer_NN
,_,
the_DT
stage_NN
-LRB-_-LRB-
degree_NN
of_IN
spread_NN
-RRB-_-RRB-
,_,
and_CC
the_DT
patient_NN
's_POS
performance_NN
status_NN
._.

Possible_JJ
treatments_NNS
include_VBP
surgery_NN
,_,
chemotherapy_NN
,_,
and_CC
radiotherapy_NN
._.

With_IN
treatment_NN
,_,
the_DT
five-year_JJ
survival_NN
rate_NN
is_VBZ
14_CD
%_NN
._.

The_DT
vast_JJ
majority_NN
of_IN
lung_NN
cancers_NNS
are_VBP
carcinomas_NNS
--_:
malignancies_NNS
that_WDT
arise_VBP
from_IN
epithelial_JJ
cells_NNS
._.

There_EX
are_VBP
two_CD
main_JJ
types_NNS
of_IN
lung_NN
carcinoma_NN
,_,
categorized_VBN
by_IN
the_DT
size_NN
and_CC
appearance_NN
of_IN
the_DT
malignant_JJ
cells_NNS
seen_VBN
by_IN
a_DT
histopathologist_JJ
under_IN
a_DT
microscope_NN
:_:
non-small_JJ
cell_NN
-LRB-_-LRB-
80.4_CD
%_NN
-RRB-_-RRB-
and_CC
small-cell_JJ
-LRB-_-LRB-
16.8_CD
%_NN
-RRB-_-RRB-
lung_NN
carcinoma_NN
._.

This_DT
classification_NN
,_,
based_VBN
on_IN
histological_JJ
criteria_NNS
,_,
has_VBZ
important_JJ
implications_NNS
for_IN
clinical_JJ
management_NN
and_CC
prognosis_NN
of_IN
the_DT
disease_NN
._.

The_DT
non-small_JJ
cell_NN
lung_NN
carcinomas_NNS
are_VBP
grouped_VBN
together_RB
because_IN
their_PRP$
prognosis_NN
and_CC
management_NN
are_VBP
similar_JJ
._.

There_EX
are_VBP
three_CD
main_JJ
sub-types_NNS
:_:
squamous_JJ
cell_NN
lung_NN
carcinoma_NN
,_,
adenocarcinoma_NN
and_CC
large_JJ
cell_NN
lung_NN
carcinoma_NN
._.

Accounting_NNP
for_IN
31.1_CD
%_NN
of_IN
lung_NN
cancers_NNS
,_,
squamous_JJ
cell_NN
lung_NN
carcinoma_NN
usually_RB
starts_VBZ
near_IN
a_DT
central_JJ
bronchus_NNS
._.

Cavitation_NN
and_CC
necrosis_NNS
within_IN
the_DT
center_NN
of_IN
the_DT
cancer_NN
is_VBZ
a_DT
common_JJ
finding_NN
._.

Well-differentiated_JJ
squamous_JJ
cell_NN
lung_NN
cancers_NNS
often_RB
grow_VBP
more_RBR
slowly_RB
than_IN
other_JJ
cancer_NN
types_NNS
._.

Adenocarcinoma_NNP
accounts_VBZ
for_IN
29.4_CD
%_NN
of_IN
lung_NN
cancers_NNS
._.

It_PRP
usually_RB
originates_VBZ
in_IN
peripheral_JJ
lung_NN
tissue_NN
._.

Most_JJS
cases_NNS
of_IN
adenocarcinoma_NN
are_VBP
associated_VBN
with_IN
smoking_NN
._.

However_RB
,_,
among_IN
people_NNS
who_WP
have_VBP
never_RB
smoked_VBN
-LRB-_-LRB-
``_``
never-smokers_JJ
''_''
-RRB-_-RRB-
,_,
adenocarcinoma_NN
is_VBZ
the_DT
most_RBS
common_JJ
form_NN
of_IN
lung_NN
cancer_NN
._.

A_DT
subtype_NN
of_IN
adenocarcinoma_NN
,_,
the_DT
bronchioloalveolar_NN
carcinoma_NN
,_,
is_VBZ
more_RBR
common_JJ
in_IN
female_JJ
never-smokers_NNS
,_,
and_CC
may_MD
have_VB
different_JJ
responses_NNS
to_TO
treatment_NN
._.

Accounting_NNP
for_IN
10.7_CD
%_NN
of_IN
lung_NN
cancers_NNS
,_,
large_JJ
cell_NN
lung_NN
carcinoma_NN
is_VBZ
a_DT
fast-growing_JJ
form_NN
that_WDT
develops_VBZ
near_IN
the_DT
surface_NN
of_IN
the_DT
lung_NN
._.

It_PRP
is_VBZ
often_RB
poorly_RB
differentiated_JJ
and_CC
tends_VBZ
to_TO
metastasize_VB
early_RB
._.

Small_JJ
cell_NN
lung_NN
carcinoma_NN
-LRB-_-LRB-
SCLC_VBN
,_,
also_RB
called_VBN
``_``
oat_NN
cell_NN
carcinoma_NN
''_''
-RRB-_-RRB-
is_VBZ
less_RBR
common_JJ
._.

It_PRP
tends_VBZ
to_TO
arise_VB
in_IN
the_DT
larger_JJR
airways_NNS
-LRB-_-LRB-
primary_JJ
and_CC
secondary_JJ
bronchi_NNS
-RRB-_-RRB-
and_CC
grows_VBZ
rapidly_RB
,_,
becoming_VBG
quite_RB
large_JJ
._.

The_DT
``_``
oat_NN
''_''
cell_NN
contains_VBZ
dense_JJ
neurosecretory_NN
granules_NNS
-LRB-_-LRB-
vesicles_NNS
containing_VBG
neuroendocrine_JJ
hormones_NNS
-RRB-_-RRB-
which_WDT
give_VBP
this_DT
an_DT
endocrine/paraneoplastic_JJ
syndrome_NN
association_NN
._.

While_IN
initially_RB
more_RBR
sensitive_JJ
to_TO
chemotherapy_NN
,_,
it_PRP
ultimately_RB
carries_VBZ
a_DT
worse_JJR
prognosis_NN
and_CC
is_VBZ
often_RB
metastatic_JJ
at_IN
presentation_NN
._.

Small_JJ
cell_NN
lung_NN
cancers_NNS
are_VBP
divided_VBN
into_IN
Limited_JJ
stage_NN
and_CC
Extensive_NN
stage_NN
disease_NN
._.

This_DT
type_NN
of_IN
lung_NN
cancer_NN
is_VBZ
strongly_RB
associated_VBN
with_IN
smoking_NN
._.

The_DT
lung_NN
is_VBZ
a_DT
common_JJ
place_NN
for_IN
metastasis_NNS
from_IN
tumors_NNS
in_IN
other_JJ
parts_NNS
of_IN
the_DT
body_NN
._.

These_DT
cancers_NNS
are_VBP
identified_VBN
by_IN
the_DT
site_NN
of_IN
origin_NN
,_,
thus_RB
a_DT
breast_NN
cancer_NN
metastasis_NN
to_TO
the_DT
lung_NN
is_VBZ
still_RB
known_VBN
as_IN
breast_NN
cancer_NN
._.

They_PRP
often_RB
have_VBP
a_DT
characteristic_JJ
round_NN
appearance_NN
on_IN
chest_NN
x-ray_NN
._.

Primary_JJ
lung_NN
cancers_NNS
themselves_PRP
most_RBS
commonly_RB
metastasize_VBP
to_TO
the_DT
adrenal_JJ
glands_NNS
,_,
liver_NN
,_,
brain_NN
,_,
and_CC
bone_NN
._.

Lung_NNP
cancer_NN
staging_NN
is_VBZ
an_DT
assessment_NN
of_IN
the_DT
degree_NN
of_IN
spread_NN
of_IN
the_DT
cancer_NN
from_IN
its_PRP$
original_JJ
source_NN
._.

It_PRP
is_VBZ
an_DT
important_JJ
factor_NN
affecting_VBG
the_DT
prognosis_NN
and_CC
potential_JJ
treatment_NN
of_IN
lung_NN
cancer_NN
._.

Non-small_NNP
cell_NN
lung_NN
carcinoma_NN
is_VBZ
staged_VBD
from_IN
IA_NNP
-LRB-_-LRB-
``_``
one_CD
A_NN
''_''
,_,
best_JJS
prognosis_NNS
-RRB-_-RRB-
to_TO
IV_NNP
-LRB-_-LRB-
``_``
four_CD
''_''
,_,
worst_IN
prognosis_NN
-RRB-_-RRB-
._.

Small_JJ
cell_NN
lung_NN
carcinoma_NN
is_VBZ
classified_JJ
as_IN
limited_JJ
stage_NN
if_IN
it_PRP
is_VBZ
confined_VBN
to_TO
one_CD
half_NN
of_IN
the_DT
chest_NN
and_CC
within_IN
the_DT
scope_NN
of_IN
a_DT
single_JJ
radiotherapy_NN
field_NN
._.

Otherwise_RB
it_PRP
is_VBZ
extensive_JJ
stage_NN
._.

Symptoms_NNS
that_WDT
suggest_VBP
lung_NN
cancer_NN
include_VBP
:_:
If_IN
the_DT
cancer_NN
grows_VBZ
in_IN
the_DT
airway_NN
,_,
it_PRP
may_MD
obstruct_VB
airflow_NN
,_,
causing_VBG
breathing_NN
difficulties_NNS
._.

This_DT
can_MD
lead_VB
to_TO
accumulation_NN
of_IN
secretions_NNS
behind_IN
the_DT
blockage_NN
,_,
predisposing_VBG
the_DT
patient_NN
to_TO
pneumonia_NN
._.

Many_JJ
lung_NN
cancers_NNS
have_VBP
a_DT
rich_JJ
blood_NN
supply_NN
._.

The_DT
surface_NN
of_IN
the_DT
cancer_NN
may_MD
be_VB
fragile_JJ
,_,
leading_VBG
to_TO
bleeding_VBG
from_IN
the_DT
cancer_NN
into_IN
the_DT
airway_NN
._.

This_DT
blood_NN
may_MD
subsequently_RB
be_VB
coughed_VBN
up_RP
._.

Depending_VBG
on_IN
the_DT
type_NN
of_IN
tumor_NN
,_,
so-called_JJ
paraneoplastic_JJ
phenomena_NNS
may_MD
initially_RB
attract_VB
attention_NN
to_TO
the_DT
disease_NN
._.

In_IN
lung_NN
cancer_NN
,_,
these_DT
phenomena_NNS
may_MD
include_VB
Lambert-Eaton_JJ
myasthenic_JJ
syndrome_NN
-LRB-_-LRB-
muscle_NN
weakness_NN
due_JJ
to_TO
auto-antibodies_NNS
-RRB-_-RRB-
,_,
hypercalcemia_NN
or_CC
syndrome_NN
of_IN
inappropriate_JJ
antidiuretic_JJ
hormone_NN
-LRB-_-LRB-
SIADH_NNP
-RRB-_-RRB-
._.

Tumors_NNS
in_IN
the_DT
top_NN
-LRB-_-LRB-
apex_NN
-RRB-_-RRB-
of_IN
the_DT
lung_NN
,_,
known_VBN
as_IN
Pancoast_NNP
tumors_NNS
,_,
may_MD
invade_VB
the_DT
local_JJ
part_NN
of_IN
the_DT
sympathetic_JJ
nervous_JJ
system_NN
,_,
leading_JJ
to_TO
changed_JJ
sweating_NN
patterns_NNS
and_CC
eye_NN
muscle_NN
problems_NNS
-LRB-_-LRB-
a_DT
combination_NN
known_VBN
as_IN
Horner_NNP
's_POS
syndrome_NN
-RRB-_-RRB-
,_,
as_RB
well_RB
as_IN
muscle_NN
weakness_NN
in_IN
the_DT
hands_NNS
due_JJ
to_TO
invasion_NN
of_IN
the_DT
brachial_JJ
plexus_NNS
._.

Many_JJ
of_IN
the_DT
symptoms_NNS
of_IN
lung_NN
cancer_NN
-LRB-_-LRB-
bone_NN
pain_NN
,_,
fever_NN
,_,
weight_NN
loss_NN
-RRB-_-RRB-
are_VBP
nonspecific_JJ
;_:
in_IN
the_DT
elderly_JJ
,_,
these_DT
may_MD
be_VB
attributed_VBN
to_TO
comorbid_JJ
illness_NN
._.

In_IN
many_JJ
patients_NNS
,_,
the_DT
cancer_NN
has_VBZ
already_RB
spread_VBN
beyond_IN
the_DT
original_JJ
site_NN
by_IN
the_DT
time_NN
they_PRP
have_VB
symptoms_NNS
and_CC
seek_VB
medical_JJ
attention_NN
._.

Common_JJ
sites_NNS
of_IN
metastasis_NNS
include_VBP
the_DT
bone_NN
,_,
such_JJ
as_IN
the_DT
spine_NN
-LRB-_-LRB-
causing_VBG
back_RP
pain_NN
and_CC
occasionally_RB
spinal_JJ
cord_NN
compression_NN
-RRB-_-RRB-
,_,
the_DT
liver_NN
and_CC
the_DT
brain_NN
._.

About_RB
10_CD
%_NN
of_IN
people_NNS
with_IN
lung_NN
cancer_NN
do_VBP
not_RB
have_VB
symptoms_NNS
at_IN
diagnosis_NN
;_:
these_DT
cancers_NNS
are_VBP
incidentally_RB
found_VBN
on_IN
routine_JJ
chest_NN
x-rays_NNS
._.

The_DT
main_JJ
causes_NNS
of_IN
lung_NN
cancer_NN
-LRB-_-LRB-
and_CC
cancer_NN
in_IN
general_NN
-RRB-_-RRB-
include_VBP
carcinogens_NNS
-LRB-_-LRB-
such_JJ
as_IN
those_DT
in_IN
tobacco_NN
smoke_NN
-RRB-_-RRB-
,_,
ionizing_VBG
radiation_NN
,_,
and_CC
viral_JJ
infection_NN
._.

This_DT
exposure_NN
causes_VBZ
cumulative_JJ
changes_NNS
to_TO
the_DT
DNA_NN
in_IN
the_DT
tissue_NN
lining_VBG
the_DT
bronchi_NN
of_IN
the_DT
lungs_NNS
-LRB-_-LRB-
the_DT
bronchial_JJ
epithelium_NN
-RRB-_-RRB-
._.

As_IN
more_JJR
tissue_NN
becomes_VBZ
damaged_JJ
,_,
eventually_RB
a_DT
cancer_NN
develops_VBZ
._.

Smoking_NN
,_,
particularly_RB
of_IN
cigarettes_NNS
,_,
is_VBZ
by_IN
far_RB
the_DT
main_JJ
contributor_NN
to_TO
lung_NN
cancer_NN
._.

In_IN
the_DT
United_NNP
States_NNPS
,_,
smoking_NN
is_VBZ
estimated_VBN
to_TO
account_VB
for_IN
87_CD
%_NN
of_IN
lung_NN
cancer_NN
cases_NNS
-LRB-_-LRB-
90_CD
%_NN
in_IN
men_NNS
and_CC
85_CD
%_NN
in_IN
women_NNS
-RRB-_-RRB-
._.

Among_IN
male_JJ
smokers_NNS
,_,
the_DT
lifetime_NN
risk_NN
of_IN
developing_VBG
lung_NN
cancer_NN
is_VBZ
17.2_CD
%_NN
._.

Among_IN
female_JJ
smokers_NNS
,_,
the_DT
risk_NN
is_VBZ
11.6_CD
%_NN
._.

This_DT
risk_NN
is_VBZ
significantly_RB
lower_JJR
in_IN
non-smokers_NNS
:_:
1.3_CD
%_NN
in_IN
men_NNS
and_CC
1.4_CD
%_NN
in_IN
women_NNS
._.

Cigarette_JJ
smoke_NN
contains_VBZ
over_IN
60_CD
known_VBN
carcinogens_NNS
including_VBG
radioisotopes_NNS
from_IN
the_DT
radon_JJ
decay_NN
sequence_NN
,_,
nitrosamine_NN
,_,
and_CC
benzopyrene_NN
._.

Additionally_RB
,_,
nicotine_NN
appears_VBZ
to_TO
depress_VB
the_DT
immune_JJ
response_NN
to_TO
malignant_JJ
growths_NNS
in_IN
exposed_VBN
tissue_NN
._.

The_DT
length_NN
of_IN
time_NN
a_DT
person_NN
smokes_VBZ
as_RB
well_RB
as_IN
the_DT
amount_NN
smoked_VBN
increases_VBZ
the_DT
person_NN
's_POS
chance_NN
of_IN
developing_VBG
lung_NN
cancer_NN
._.

If_IN
a_DT
person_NN
stops_VBZ
smoking_NN
,_,
this_DT
chance_NN
steadily_RB
decreases_VBZ
as_IN
damage_NN
to_TO
the_DT
lungs_NNS
is_VBZ
repaired_VBN
and_CC
contaminant_NN
particles_NNS
are_VBP
gradually_RB
removed_VBN
._.

Across_IN
the_DT
developed_JJ
world_NN
,_,
almost_RB
90_CD
%_NN
of_IN
lung_NN
cancer_NN
deaths_NNS
are_VBP
caused_VBN
by_IN
smoking_NN
._.

In_IN
addition_NN
,_,
there_EX
is_VBZ
evidence_NN
that_IN
lung_NN
cancer_NN
in_IN
never-smokers_NNS
has_VBZ
a_DT
better_JJR
prognosis_NN
than_IN
in_IN
smokers_NNS
,_,
and_CC
that_IN
patients_NNS
who_WP
smoke_VBP
at_IN
the_DT
time_NN
of_IN
diagnosis_NN
have_VBP
shorter_JJR
survival_NN
than_IN
those_DT
who_WP
have_VBP
quit_VBN
._.

Passive_NNP
smoking_NN
--_:
the_DT
inhalation_NN
of_IN
smoke_NN
from_IN
another_DT
's_POS
smoking_NN
--_:
is_VBZ
a_DT
cause_NN
of_IN
lung_NN
cancer_NN
in_IN
non-smokers_NNS
._.

Studies_NNS
from_IN
the_DT
U.S_NNP
._.

,_,
Europe_NNP
,_,
the_DT
UK_NNP
,_,
and_CC
Australia_NNP
have_VBP
consistently_RB
shown_VBN
a_DT
significant_JJ
increase_NN
in_IN
relative_JJ
risk_NN
among_IN
those_DT
exposed_VBN
to_TO
passive_JJ
smoke_NN
._.

Recent_JJ
investigation_NN
of_IN
sidestream_NN
smoke_NN
suggests_VBZ
it_PRP
is_VBZ
more_RBR
dangerous_JJ
than_IN
direct_JJ
smoke_NN
inhalation_NN
._.

Radon_NNP
is_VBZ
a_DT
colorless_NNS
and_CC
odorless_NNS
gas_NN
generated_VBN
by_IN
the_DT
breakdown_NN
of_IN
radioactive_JJ
radium_NN
,_,
which_WDT
in_IN
turn_NN
is_VBZ
the_DT
decay_NN
product_NN
of_IN
uranium_NN
,_,
found_VBN
in_IN
the_DT
earth_NN
's_POS
crust_NN
._.

The_DT
radiation_NN
decay_NN
products_NNS
ionize_VBP
genetic_JJ
material_NN
,_,
causing_VBG
mutations_NNS
that_WDT
sometimes_RB
turn_VBP
cancerous_JJ
._.

Radon_NN
exposure_NN
is_VBZ
the_DT
second_JJ
major_JJ
cause_NN
of_IN
lung_NN
cancer_NN
after_IN
smoking_NN
._.

Radon_NNP
gas_NN
levels_NNS
vary_VBP
by_IN
locality_NN
and_CC
the_DT
composition_NN
of_IN
the_DT
underlying_JJ
soil_NN
and_CC
rocks_NNS
._.

For_IN
example_NN
,_,
in_IN
areas_NNS
such_JJ
as_IN
Cornwall_NNP
in_IN
the_DT
UK_NNP
-LRB-_-LRB-
which_WDT
has_VBZ
granite_NN
as_IN
substrata_NN
-RRB-_-RRB-
,_,
radon_NN
gas_NN
is_VBZ
a_DT
major_JJ
problem_NN
,_,
and_CC
buildings_NNS
have_VBP
to_TO
be_VB
force-ventilated_VBN
with_IN
fans_NNS
to_TO
lower_JJR
radon_NN
gas_NN
concentrations_NNS
._.

The_DT
United_NNP
States_NNPS
Environmental_NNP
Protection_NNP
Agency_NNP
-LRB-_-LRB-
EPA_NNP
-RRB-_-RRB-
estimates_VBZ
that_DT
one_NN
in_IN
15_CD
homes_NNS
in_IN
the_DT
U.S_NNP
._.

has_VBZ
radon_NN
levels_NNS
above_IN
the_DT
recommended_VBN
guideline_NN
of_IN
4_CD
picocuries_NNS
per_IN
liter_NN
-LRB-_-LRB-
pCi/L_JJ
-RRB-_-RRB-
-LRB-_-LRB-
148_CD
Bq/m_NNP
Â³_NNS
-RRB-_-RRB-
._.

Iowa_NNP
has_VBZ
the_DT
highest_JJS
average_JJ
radon_NN
concentration_NN
in_IN
the_DT
United_NNP
States_NNPS
;_:
studies_NNS
performed_VBD
there_EX
have_VBP
demonstrated_VBN
a_DT
50_CD
%_NN
increased_VBN
lung_NN
cancer_NN
risk_NN
with_IN
prolonged_JJ
radon_NN
exposure_NN
above_IN
the_DT
EPA_NNP
's_POS
action_NN
level_NN
of_IN
4_CD
pCi/L_NN
._.

Asbestos_NN
can_MD
cause_VB
a_DT
variety_NN
of_IN
lung_NN
diseases_NNS
,_,
including_VBG
lung_NN
cancer_NN
._.

There_EX
is_VBZ
a_DT
synergistic_JJ
effect_NN
between_IN
tobacco_NN
smoking_NN
and_CC
asbestos_NN
in_IN
the_DT
formation_NN
of_IN
lung_NN
cancer_NN
._.

In_IN
the_DT
UK_NNP
,_,
asbestos_NN
accounts_VBZ
for_IN
2_CD
--_:
3_CD
%_NN
of_IN
male_JJ
lung_NN
cancer_NN
deaths_NNS
._.

Asbestos_NN
can_MD
also_RB
cause_VB
cancer_NN
of_IN
the_DT
pleura_NN
,_,
called_VBN
mesothelioma_NN
-LRB-_-LRB-
which_WDT
is_VBZ
different_JJ
from_IN
lung_NN
cancer_NN
-RRB-_-RRB-
._.

Viruses_NNS
are_VBP
known_VBN
to_TO
cause_VB
lung_NN
cancer_NN
in_IN
animals_NNS
and_CC
recent_JJ
evidence_NN
suggests_VBZ
similar_JJ
potential_NN
in_IN
humans_NNS
._.

Implicated_JJ
viruses_NNS
include_VBP
human_JJ
papillomavirus_NNS
,_,
JC_VBP
virus_NN
,_,
simian_NN
virus_NN
40_CD
-LRB-_-LRB-
SV40_NNP
-RRB-_-RRB-
,_,
BK_NNP
virus_NN
and_CC
cytomegalovirus_NNS
._.

These_DT
viruses_NNS
may_MD
affect_VB
the_DT
cell_NN
cycle_NN
and_CC
inhibit_VB
apoptosis_NNS
,_,
allowing_VBG
uncontrolled_JJ
cell_NN
division_NN
._.

Similar_VBG
to_TO
many_JJ
other_JJ
cancers_NNS
,_,
lung_NN
cancer_NN
is_VBZ
initiated_VBN
by_IN
activation_NN
of_IN
oncogenes_NNS
or_CC
inactivation_NN
of_IN
tumor_NN
suppressor_NN
genes_NNS
._.

Oncogenes_NNS
are_VBP
genes_NNS
that_WDT
are_VBP
believed_VBN
to_TO
make_VB
people_NNS
more_RBR
susceptible_JJ
to_TO
cancer_NN
._.

Proto-oncogenes_NNS
are_VBP
believed_VBN
to_TO
turn_VB
into_IN
oncogenes_NNS
when_WRB
exposed_VBN
to_TO
particular_JJ
carcinogens_NNS
._.

Mutations_NNS
in_IN
the_DT
K-ras_NNP
proto-oncogene_NN
are_VBP
responsible_JJ
for_IN
20_CD
--_:
30_CD
%_NN
of_IN
non-small_JJ
cell_NN
lung_NN
cancers_NNS
._.

Chromosomal_JJ
damage_NN
can_MD
lead_VB
to_TO
loss_NN
of_IN
heterozygosity_NN
._.

This_DT
can_MD
cause_VB
inactivation_NN
of_IN
tumor_NN
suppressor_NN
genes_NNS
._.

Damage_NN
to_TO
chromosomes_NNP
3p_CD
,_,
5q_CD
,_,
13q_CD
and_CC
17p_CD
are_VBP
particularly_RB
common_JJ
in_IN
small_JJ
cell_NN
lung_NN
carcinoma_NN
._.

The_DT
TP53_NNP
tumor_NN
suppressor_NN
gene_NN
,_,
located_VBN
on_IN
chromosome_NN
17p_NNS
,_,
is_VBZ
often_RB
affected_VBN
._.

Several_JJ
genetic_JJ
polymorphisms_NNS
are_VBP
associated_VBN
with_IN
lung_NN
cancer_NN
._.

These_DT
include_VBP
polymorphisms_NNS
in_IN
genes_NNS
coding_VBG
for_IN
interleukin-1_JJ
,_,
cytochrome_JJ
P450_NN
,_,
apoptosis_NN
promoters_NNS
such_JJ
as_IN
caspase-8_JJ
,_,
and_CC
DNA_NN
repair_NN
molecules_NNS
such_JJ
as_IN
XRCC1_NNP
._.

People_NNS
with_IN
these_DT
polymorphisms_NNS
are_VBP
more_RBR
likely_JJ
to_TO
develop_VB
lung_NN
cancer_NN
after_IN
exposure_NN
to_TO
carcinogens_NNS
._.

Performing_VBG
a_DT
chest_NN
x-ray_NN
is_VBZ
the_DT
first_JJ
step_NN
if_IN
a_DT
patient_NN
reports_VBZ
symptoms_NNS
that_WDT
may_MD
be_VB
suggestive_NN
of_IN
lung_NN
cancer_NN
._.

This_DT
may_MD
reveal_VB
an_DT
obvious_JJ
mass_NN
,_,
widening_NN
of_IN
the_DT
mediastinum_NN
-LRB-_-LRB-
suggestive_NN
of_IN
spread_NN
to_TO
lymph_NN
nodes_NNS
there_EX
-RRB-_-RRB-
,_,
atelectasis_NNS
-LRB-_-LRB-
collapse_NN
-RRB-_-RRB-
,_,
consolidation_NN
-LRB-_-LRB-
pneumonia_NN
-RRB-_-RRB-
,_,
or_CC
pleural_JJ
effusion_NN
._.

If_IN
there_EX
are_VBP
no_DT
x-ray_JJ
findings_NNS
but_CC
the_DT
suspicion_NN
is_VBZ
high_JJ
-LRB-_-LRB-
such_JJ
as_IN
a_DT
heavy_JJ
smoker_NN
with_IN
blood-stained_JJ
sputum_NN
-RRB-_-RRB-
,_,
bronchoscopy_NN
and/or_VBD
a_DT
CT_NNP
scan_NNP
may_MD
provide_VB
the_DT
necessary_JJ
information_NN
._.

Bronchoscopy_NNP
or_CC
CT-guided_NNP
biopsy_RB
is_VBZ
often_RB
used_VBN
to_TO
identify_VB
the_DT
tumor_NN
type_NN
._.

The_DT
differential_NN
diagnosis_NN
for_IN
patients_NNS
who_WP
present_VBP
with_IN
abnormalities_NNS
on_IN
chest_NN
x-ray_NN
includes_VBZ
lung_NN
cancer_NN
,_,
as_RB
well_RB
as_IN
nonmalignant_JJ
diseases_NNS
._.

These_DT
include_VBP
infectious_JJ
causes_NNS
such_JJ
as_IN
tuberculosis_NNP
or_CC
pneumonia_NN
,_,
or_CC
inflammatory_JJ
conditions_NNS
such_JJ
as_IN
sarcoidosis_NNS
._.

These_DT
diseases_NNS
can_MD
result_VB
in_IN
mediastinal_JJ
lymphadenopathy_NN
or_CC
lung_NN
nodules_NNS
,_,
and_CC
sometimes_RB
mimic_VB
lung_NN
cancers_NNS
._.

Prevention_NNP
is_VBZ
the_DT
most_RBS
cost-effective_JJ
means_NN
of_IN
fighting_VBG
lung_NN
cancer_NN
._.

While_IN
in_IN
most_JJS
countries_NNS
industrial_JJ
and_CC
domestic_JJ
carcinogens_NNS
have_VBP
been_VBN
identified_VBN
and_CC
banned_VBN
,_,
tobacco_NN
smoking_NN
is_VBZ
still_RB
widespread_JJ
._.

Eliminating_VBG
tobacco_NN
smoking_NN
is_VBZ
a_DT
primary_JJ
goal_NN
in_IN
the_DT
prevention_NN
of_IN
lung_NN
cancer_NN
,_,
and_CC
smoking_NN
cessation_NN
is_VBZ
an_DT
important_JJ
preventative_JJ
tool_NN
in_IN
this_DT
process_NN
._.

Policy_NNP
interventions_NNS
to_TO
decrease_VB
passive_JJ
smoking_NN
in_IN
public_JJ
areas_NNS
such_JJ
as_IN
restaurants_NNS
and_CC
workplaces_NNS
have_VBP
become_VBN
more_RBR
common_JJ
in_IN
many_JJ
Western_JJ
countries_NNS
,_,
with_IN
California_NNP
taking_VBG
a_DT
lead_NN
in_IN
banning_VBG
smoking_NN
in_IN
public_JJ
establishments_NNS
in_IN
1998_CD
._.

Ireland_NNP
played_VBD
a_DT
similar_JJ
role_NN
in_IN
Europe_NNP
in_IN
2004_CD
,_,
followed_VBN
by_IN
Italy_NNP
and_CC
Norway_NNP
in_IN
2005_CD
,_,
Scotland_VBD
as_RB
well_RB
as_IN
several_JJ
others_NNS
in_IN
2006_CD
,_,
England_NNP
in_IN
2007_CD
,_,
and_CC
France_NNP
in_IN
2008_CD
._.

New_NNP
Zealand_NNP
has_VBZ
banned_VBN
smoking_NN
in_IN
public_JJ
places_NNS
as_RB
of_IN
2004_CD
._.

The_DT
state_NN
of_IN
Bhutan_NNP
has_VBZ
had_VBN
a_DT
complete_JJ
smoking_NN
ban_NN
since_IN
2005_CD
._.

In_IN
many_JJ
countries_NNS
,_,
pressure_NN
groups_NNS
are_VBP
campaigning_VBG
for_IN
similar_JJ
bans_NNS
._.

Arguments_NNS
cited_VBN
against_IN
such_JJ
bans_NNS
are_VBP
criminalisation_NN
of_IN
smoking_NN
,_,
increased_VBN
risk_NN
of_IN
smuggling_NN
and_CC
the_DT
risk_NN
that_IN
such_PDT
a_DT
ban_NN
can_MD
not_RB
be_VB
enforced_VBN
._.

A_DT
2008_CD
study_NN
performed_VBN
in_IN
over_IN
75_CD
,_,
000_CD
middle-aged_JJ
and_CC
elderly_JJ
people_NNS
demonstrated_VBD
that_IN
the_DT
long-term_JJ
use_NN
of_IN
supplemental_JJ
multivitamins_NNS
,_,
such_JJ
as_IN
vitamin_NNP
C_NNP
,_,
vitamin_NNP
E_NNP
,_,
and_CC
folate_NN
did_VBD
not_RB
reduce_VB
the_DT
risk_NN
of_IN
lung_NN
cancer_NN
._.

To_TO
the_DT
contrary_NN
,_,
the_DT
study_NN
indicates_VBZ
that_IN
the_DT
long_JJ
term_NN
intake_NN
of_IN
high_JJ
doses_NNS
of_IN
vitamin_NN
E_NN
supplements_NNS
may_MD
even_RB
increase_VB
the_DT
risk_NN
of_IN
lung_NN
cancer_NN
._.

Screening_NNP
refers_VBZ
to_TO
the_DT
use_NN
of_IN
medical_JJ
tests_NNS
to_TO
detect_VB
disease_NN
in_IN
asymptomatic_JJ
people_NNS
._.

Possible_JJ
screening_NN
tests_NNS
for_IN
lung_NN
cancer_NN
include_VBP
chest_NN
x-ray_JJ
or_CC
computed_JJ
tomography_NN
-LRB-_-LRB-
CT_NNP
-RRB-_-RRB-
of_IN
the_DT
chest_NN
._.

So_IN
far_RB
,_,
screening_NN
programs_NNS
for_IN
lung_NN
cancer_NN
have_VBP
not_RB
demonstrated_VBN
any_DT
clear_JJ
benefit_NN
._.

Randomized_JJ
controlled_JJ
trials_NNS
are_VBP
underway_JJ
in_IN
this_DT
area_NN
to_TO
see_VB
if_IN
decreased_VBN
long-term_JJ
mortality_NN
can_MD
be_VB
directly_RB
observed_JJ
from_IN
CT_NNP
screening_NN
._.

Treatment_NNP
for_IN
lung_NN
cancer_NN
depends_VBZ
on_IN
the_DT
cancer_NN
's_POS
specific_JJ
cell_NN
type_NN
,_,
how_WRB
far_RB
it_PRP
has_VBZ
spread_VBN
,_,
and_CC
the_DT
patient_NN
's_POS
performance_NN
status_NN
._.

Common_JJ
treatments_NNS
include_VBP
surgery_NN
,_,
chemotherapy_NN
,_,
and_CC
radiation_NN
therapy_NN
._.

If_IN
investigations_NNS
confirm_VBP
lung_NN
cancer_NN
,_,
CT_NNP
scan_NNP
and_CC
often_RB
positron_NN
emission_NN
tomography_NN
-LRB-_-LRB-
PET_NNP
-RRB-_-RRB-
are_VBP
used_VBN
to_TO
determine_VB
whether_IN
the_DT
disease_NN
is_VBZ
localised_JJ
and_CC
amenable_JJ
to_TO
surgery_NN
or_CC
whether_IN
it_PRP
has_VBZ
spread_VBN
to_TO
the_DT
point_NN
where_WRB
it_PRP
can_MD
not_RB
be_VB
cured_VBN
surgically_RB
._.

Blood_NN
tests_NNS
and_CC
spirometry_NN
-LRB-_-LRB-
lung_NN
function_NN
testing_NN
-RRB-_-RRB-
are_VBP
also_RB
necessary_JJ
to_TO
assess_VB
whether_IN
the_DT
patient_NN
is_VBZ
well_RB
enough_JJ
to_TO
be_VB
operated_VBN
on_RP
._.

If_IN
spirometry_RB
reveals_VBZ
poor_JJ
respiratory_NN
reserve_NN
-LRB-_-LRB-
often_RB
due_JJ
to_TO
chronic_JJ
obstructive_JJ
pulmonary_JJ
disease_NN
-RRB-_-RRB-
,_,
surgery_NN
may_MD
be_VB
contraindicated_VBN
._.

Surgery_RB
itself_PRP
has_VBZ
an_DT
operative_JJ
death_NN
rate_NN
of_IN
about_RB
4.4_CD
%_NN
,_,
depending_VBG
on_IN
the_DT
patient_NN
's_POS
lung_NN
function_NN
and_CC
other_JJ
risk_NN
factors_NNS
._.

Surgery_NNP
is_VBZ
usually_RB
only_RB
an_DT
option_NN
in_IN
non-small_JJ
cell_NN
lung_NN
carcinoma_NN
limited_VBN
to_TO
one_CD
lung_NN
,_,
up_RB
to_TO
stage_VB
IIIA_NNP
._.

This_DT
is_VBZ
assessed_VBN
with_IN
medical_JJ
imaging_NN
-LRB-_-LRB-
computed_JJ
tomography_NN
,_,
positron_NN
emission_NN
tomography_NN
-RRB-_-RRB-
._.

A_DT
sufficient_JJ
pre-operative_JJ
respiratory_NN
reserve_NN
must_MD
be_VB
present_JJ
to_TO
allow_VB
adequate_JJ
lung_NN
function_NN
after_IN
the_DT
tissue_NN
is_VBZ
removed_VBN
._.

Procedures_NNS
include_VBP
wedge_NN
resection_NN
-LRB-_-LRB-
removal_NN
of_IN
part_NN
of_IN
a_DT
lobe_NN
-RRB-_-RRB-
,_,
segmentectomy_NN
-LRB-_-LRB-
removal_NN
of_IN
an_DT
anatomic_JJ
division_NN
of_IN
a_DT
particular_JJ
lobe_NN
of_IN
the_DT
lung_NN
-RRB-_-RRB-
,_,
lobectomy_NN
-LRB-_-LRB-
one_CD
lobe_NN
-RRB-_-RRB-
,_,
bilobectomy_NN
-LRB-_-LRB-
two_CD
lobes_NNS
-RRB-_-RRB-
or_CC
pneumonectomy_NN
-LRB-_-LRB-
whole_JJ
lung_NN
-RRB-_-RRB-
._.

In_IN
patients_NNS
with_IN
adequate_JJ
respiratory_JJ
reserve_NN
,_,
lobectomy_NN
is_VBZ
the_DT
preferred_JJ
option_NN
,_,
as_IN
this_DT
minimizes_VBZ
the_DT
chance_NN
of_IN
local_JJ
recurrence_NN
._.

If_IN
the_DT
patient_NN
does_VBZ
not_RB
have_VB
enough_RB
functional_JJ
lung_NN
for_IN
this_DT
,_,
wedge_NN
resection_NN
may_MD
be_VB
performed_VBN
._.

Radioactive_JJ
iodine_NN
brachytherapy_NN
at_IN
the_DT
margins_NNS
of_IN
wedge_NN
excision_NN
may_MD
reduce_VB
recurrence_NN
to_TO
that_DT
of_IN
lobectomy_NN
._.

Small_JJ
cell_NN
lung_NN
carcinoma_NN
is_VBZ
treated_VBN
primarily_RB
with_IN
chemotherapy_NN
and_CC
radiation_NN
,_,
as_IN
surgery_NN
has_VBZ
no_DT
demonstrable_JJ
influence_NN
on_IN
survival_NN
._.

Primary_JJ
chemotherapy_NN
is_VBZ
also_RB
given_VBN
in_IN
metastatic_JJ
non-small_JJ
cell_NN
lung_NN
carcinoma_NN
._.

The_DT
combination_NN
regimen_NN
depends_VBZ
on_IN
the_DT
tumor_NN
type_NN
._.

Non-small_NNP
cell_NN
lung_NN
carcinoma_NN
is_VBZ
often_RB
treated_VBN
with_IN
cisplatin_NN
or_CC
carboplatin_NN
,_,
in_IN
combination_NN
with_IN
gemcitabine_JJ
,_,
paclitaxel_JJ
,_,
docetaxel_JJ
,_,
etoposide_JJ
or_CC
vinorelbine_JJ
._.

In_IN
small_JJ
cell_NN
lung_NN
carcinoma_NN
,_,
cisplatin_NN
and_CC
etoposide_NN
are_VBP
most_RBS
commonly_RB
used_VBN
._.

Combinations_NNS
with_IN
carboplatin_NN
,_,
gemcitabine_NN
,_,
paclitaxel_NN
,_,
vinorelbine_NN
,_,
topotecan_NN
and_CC
irinotecan_NN
are_VBP
also_RB
used_VBN
._.

Adjuvant_NNP
chemotherapy_RB
refers_VBZ
to_TO
the_DT
use_NN
of_IN
chemotherapy_NN
after_IN
surgery_NN
to_TO
improve_VB
the_DT
outcome_NN
._.

During_IN
surgery_NN
,_,
samples_NNS
are_VBP
taken_VBN
from_IN
the_DT
lymph_NN
nodes_NNS
._.

If_IN
these_DT
samples_NNS
contain_VBP
cancer_NN
,_,
then_RB
the_DT
patient_NN
has_VBZ
stage_NNP
II_NNP
or_CC
III_NNP
disease_NN
._.

In_IN
this_DT
situation_NN
,_,
adjuvant_NN
chemotherapy_NN
may_MD
improve_VB
survival_NN
by_IN
up_IN
to_TO
15_CD
%_NN
._.

Standard_NNP
practice_NN
is_VBZ
to_TO
offer_VB
platinum-based_JJ
chemotherapy_NN
-LRB-_-LRB-
including_VBG
either_DT
cisplatin_NN
or_CC
carboplatin_NN
-RRB-_-RRB-
._.

Adjuvant_JJ
chemotherapy_NN
for_IN
patients_NNS
with_IN
stage_NN
IB_NN
cancer_NN
is_VBZ
controversial_JJ
as_IN
clinical_JJ
trials_NNS
have_VBP
not_RB
clearly_RB
demonstrated_VBN
a_DT
survival_NN
benefit_NN
._.

Trials_NNS
of_IN
preoperative_JJ
chemotherapy_NN
-LRB-_-LRB-
neoadjuvant_JJ
chemotherapy_NN
-RRB-_-RRB-
in_IN
resectable_JJ
non-small_JJ
cell_NN
lung_NN
carcinoma_NN
have_VBP
been_VBN
inconclusive_JJ
._.

Radiotherapy_NNP
is_VBZ
often_RB
given_VBN
together_RB
with_IN
chemotherapy_NN
,_,
and_CC
may_MD
be_VB
used_VBN
with_IN
curative_JJ
intent_NN
in_IN
patients_NNS
with_IN
non-small_JJ
cell_NN
lung_NN
carcinoma_NN
who_WP
are_VBP
not_RB
eligible_JJ
for_IN
surgery_NN
._.

This_DT
form_NN
of_IN
high_JJ
intensity_NN
radiotherapy_RB
is_VBZ
called_VBN
radical_JJ
radiotherapy_RB
._.

A_DT
refinement_NN
of_IN
this_DT
technique_NN
is_VBZ
continuous_JJ
hyperfractionated_JJ
accelerated_JJ
radiotherapy_NN
-LRB-_-LRB-
CHART_NNP
-RRB-_-RRB-
,_,
where_WRB
a_DT
high_JJ
dose_NN
of_IN
radiotherapy_NN
is_VBZ
given_VBN
in_IN
a_DT
short_JJ
time_NN
period_NN
._.

For_IN
small_JJ
cell_NN
lung_NN
carcinoma_NN
cases_NNS
that_WDT
are_VBP
potentially_RB
curable_JJ
,_,
in_IN
addition_NN
to_TO
chemotherapy_NN
,_,
chest_NN
radiation_NN
is_VBZ
often_RB
recommended_VBN
._.

The_DT
use_NN
of_IN
adjuvant_JJ
thoracic_JJ
radiotherapy_NN
following_VBG
curative_JJ
intent_NN
surgery_NN
for_IN
non-small_JJ
cell_NN
lung_NN
carcinoma_NN
is_VBZ
not_RB
well_RB
established_VBN
and_CC
controversial_JJ
._.

Benefits_NNS
,_,
if_IN
any_DT
,_,
may_MD
only_RB
be_VB
limited_VBN
to_TO
those_DT
in_IN
whom_WP
the_DT
tumor_NN
has_VBZ
spread_VBN
to_TO
the_DT
mediastinal_JJ
lymph_NN
nodes_NNS
._.

For_IN
both_DT
non-small_JJ
cell_NN
lung_NN
carcinoma_NN
and_CC
small_JJ
cell_NN
lung_NN
carcinoma_NN
patients_NNS
,_,
smaller_JJR
doses_NNS
of_IN
radiation_NN
to_TO
the_DT
chest_NN
may_MD
be_VB
used_VBN
for_IN
symptom_NN
control_NN
-LRB-_-LRB-
palliative_JJ
radiotherapy_NN
-RRB-_-RRB-
._.

Unlike_IN
other_JJ
treatments_NNS
,_,
it_PRP
is_VBZ
possible_JJ
to_TO
deliver_VB
palliative_JJ
radiotherapy_NN
without_IN
confirming_VBG
the_DT
histological_JJ
diagnosis_NN
of_IN
lung_NN
cancer_NN
._.

Patients_NNS
with_IN
limited_JJ
stage_NN
small_JJ
cell_NN
lung_NN
carcinoma_NNS
are_VBP
usually_RB
given_VBN
prophylactic_JJ
cranial_JJ
irradiation_NN
-LRB-_-LRB-
PCI_NNP
-RRB-_-RRB-
._.

This_DT
is_VBZ
a_DT
type_NN
of_IN
radiotherapy_NN
to_TO
the_DT
brain_NN
,_,
used_VBN
to_TO
reduce_VB
the_DT
risk_NN
of_IN
metastasis_NNS
._.

More_RBR
recently_RB
,_,
PCI_NNP
has_VBZ
also_RB
been_VBN
shown_VBN
to_TO
be_VB
beneficial_JJ
in_IN
those_DT
with_IN
extensive_JJ
small_JJ
cell_NN
lung_NN
cancer_NN
._.

In_IN
patients_NNS
whose_WP$
cancer_NN
has_VBZ
improved_VBN
following_VBG
a_DT
course_NN
of_IN
chemotherapy_NN
,_,
PCI_NNP
has_VBZ
been_VBN
shown_VBN
to_TO
reduce_VB
the_DT
cumulative_JJ
risk_NN
of_IN
brain_NN
metastases_NNS
within_IN
one_CD
year_NN
from_IN
40.4_CD
%_NN
to_TO
14.6_CD
%_NN
._.

Recent_JJ
improvements_NNS
in_IN
targeting_VBG
and_CC
imaging_NN
have_VBP
led_VBN
to_TO
the_DT
development_NN
of_IN
extracranial_JJ
stereotactic_JJ
radiation_NN
in_IN
the_DT
treatment_NN
of_IN
early-stage_JJ
lung_NN
cancer_NN
._.

In_IN
this_DT
form_NN
of_IN
radiation_NN
therapy_NN
,_,
very_RB
high_JJ
doses_NNS
are_VBP
delivered_VBN
in_IN
a_DT
small_JJ
number_NN
of_IN
sessions_NNS
using_VBG
stereotactic_JJ
targeting_VBG
techniques_NNS
._.

Its_PRP$
use_NN
is_VBZ
primarily_RB
in_IN
patients_NNS
who_WP
are_VBP
not_RB
surgical_JJ
candidates_NNS
due_JJ
to_TO
medical_JJ
comorbidities_NNS
._.

Radiofrequency_JJ
ablation_NN
should_MD
currently_RB
be_VB
considered_VBN
an_DT
investigational_JJ
technique_NN
in_IN
the_DT
treatment_NN
of_IN
bronchogenic_JJ
carcinoma_NN
._.

It_PRP
is_VBZ
done_VBN
by_IN
inserting_VBG
a_DT
small_JJ
heat_NN
probe_NN
into_IN
the_DT
tumor_NN
to_TO
kill_VB
the_DT
tumor_NN
cells_NNS
._.

In_IN
recent_JJ
years_NNS
,_,
various_JJ
molecular_JJ
targeted_JJ
therapies_NNS
have_VBP
been_VBN
developed_VBN
for_IN
the_DT
treatment_NN
of_IN
advanced_JJ
lung_NN
cancer_NN
._.

Gefitinib_NNP
-LRB-_-LRB-
Iressa_NNP
-RRB-_-RRB-
is_VBZ
one_CD
such_JJ
drug_NN
,_,
which_WDT
targets_VBZ
the_DT
tyrosine_JJ
kinase_NN
domain_NN
of_IN
the_DT
epidermal_JJ
growth_NN
factor_NN
receptor_NN
-LRB-_-LRB-
EGF-R_NNP
-RRB-_-RRB-
which_WDT
is_VBZ
expressed_VBN
in_IN
many_JJ
cases_NNS
of_IN
non-small_JJ
cell_NN
lung_NN
carcinoma_NN
._.

It_PRP
was_VBD
not_RB
shown_VBN
to_TO
increase_VB
survival_NN
,_,
although_IN
females_NNS
,_,
Asians_NNPS
,_,
non-smokers_NNS
and_CC
those_DT
with_IN
bronchioloalveolar_NN
carcinoma_NN
appear_VBP
to_TO
derive_VB
the_DT
most_JJS
benefit_NN
from_IN
gefitinib_NN
._.

Erlotinib_NNP
-LRB-_-LRB-
Tarceva_NNP
-RRB-_-RRB-
,_,
another_DT
tyrosine_JJ
kinase_NN
inhibitor_NN
,_,
has_VBZ
been_VBN
shown_VBN
to_TO
increase_VB
survival_NN
in_IN
lung_NN
cancer_NN
patients_NNS
and_CC
has_VBZ
recently_RB
been_VBN
approved_VBN
by_IN
the_DT
FDA_NNP
for_IN
second-line_JJ
treatment_NN
of_IN
advanced_VBN
non-small_JJ
cell_NN
lung_NN
carcinoma_NN
._.

Similar_VBG
to_TO
gefitinib_NN
,_,
it_PRP
appeared_VBD
to_TO
work_VB
best_JJS
in_IN
females_NNS
,_,
Asians_NNPS
,_,
non-smokers_NNS
and_CC
those_DT
with_IN
bronchioloalveolar_NN
carcinoma_NN
._.

The_DT
angiogenesis_JJ
inhibitor_NN
bevacizumab_NN
-LRB-_-LRB-
in_IN
combination_NN
with_IN
paclitaxel_NN
and_CC
carboplatin_NN
-RRB-_-RRB-
improves_VBZ
the_DT
survival_NN
of_IN
patients_NNS
with_IN
advanced_VBN
non-small_JJ
cell_NN
lung_NN
carcinoma_NN
._.

However_RB
this_DT
increases_VBZ
the_DT
risk_NN
of_IN
lung_NN
bleeding_NN
,_,
particularly_RB
in_IN
patients_NNS
with_IN
squamous_JJ
cell_NN
carcinoma_NN
._.

Advances_NNS
in_IN
cytotoxic_JJ
drugs_NNS
,_,
pharmacogenetics_NNS
and_CC
targeted_JJ
drug_NN
design_NN
show_VBP
promise_NN
._.

A_DT
number_NN
of_IN
targeted_JJ
agents_NNS
are_VBP
at_IN
the_DT
early_JJ
stages_NNS
of_IN
clinical_JJ
research_NN
,_,
such_JJ
as_IN
cyclo-oxygenase-2_JJ
inhibitors_NNS
,_,
the_DT
apoptosis_JJ
promoter_NN
exisulind_NN
,_,
proteasome_JJ
inhibitors_NNS
,_,
bexarotene_NN
and_CC
vaccines_NNS
._.

Future_JJ
areas_NNS
of_IN
research_NN
include_VBP
ras_NN
proto-oncogene_JJ
inhibition_NN
,_,
phosphoinositide_JJ
3-kinase_JJ
inhibition_NN
,_,
histone_JJ
deacetylase_NN
inhibition_NN
,_,
and_CC
tumor_NN
suppressor_NN
gene_NN
replacement_NN
._.

Prognostic_JJ
factors_NNS
in_IN
non_NN
-_:
small-cell_JJ
lung_NN
cancer_NN
include_VBP
presence_NN
or_CC
absence_NN
of_IN
pulmonary_JJ
symptoms_NNS
,_,
tumor_NN
size_NN
,_,
cell_NN
type_NN
-LRB-_-LRB-
histology_NN
-RRB-_-RRB-
,_,
degree_NN
of_IN
spread_NN
-LRB-_-LRB-
stage_NN
-RRB-_-RRB-
and_CC
metastases_NNS
to_TO
multiple_JJ
lymph_NN
nodes_NNS
,_,
and_CC
vascular_NN
invasion_NN
._.

For_IN
patients_NNS
with_IN
inoperable_JJ
disease_NN
,_,
prognosis_NN
is_VBZ
adversely_RB
affected_VBN
by_IN
poor_JJ
performance_NN
status_NN
and_CC
weight_NN
loss_NN
of_IN
more_JJR
than_IN
10_CD
%_NN
._.

National_NNP
Cancer_NNP
Institute_NNP
PDQ_NNP
for_IN
Professionals_NNP
._.

National_NNP
Cancer_NNP
Institute_NNP
PDQ_NNP
for_IN
Professionals_NNP
-RSB-_NNP
._.

For_IN
non-small_JJ
cell_NN
lung_NN
carcinoma_NN
,_,
prognosis_NN
is_VBZ
generally_RB
poor_JJ
._.

Following_VBG
complete_JJ
surgical_JJ
resection_NN
of_IN
stage_NN
IA_NN
disease_NN
,_,
five-year_JJ
survival_NN
is_VBZ
67_CD
%_NN
._.

With_IN
stage_NN
IB_NN
disease_NN
,_,
five-year_JJ
survival_NN
is_VBZ
57_CD
%_NN
._.

The_DT
5-year_JJ
survival_NN
rate_NN
of_IN
patients_NNS
with_IN
stage_NN
IV_NNP
NSCLC_NNP
is_VBZ
about_RB
1_CD
%_NN
._.

For_IN
small_JJ
cell_NN
lung_NN
carcinoma_NN
,_,
prognosis_NN
is_VBZ
also_RB
generally_RB
poor_JJ
._.

The_DT
overall_JJ
five-year_JJ
survival_NN
for_IN
patients_NNS
with_IN
SCLC_NNP
is_VBZ
about_RB
5_CD
%_NN
._.

Patients_NNS
with_IN
extensive-stage_JJ
SCLC_NN
have_VBP
an_DT
average_JJ
five-year_JJ
survival_NN
rate_NN
of_IN
less_JJR
than_IN
1_CD
%_NN
._.

The_DT
median_JJ
survival_NN
time_NN
for_IN
limited-stage_JJ
disease_NN
is_VBZ
20_CD
months_NNS
,_,
with_IN
a_DT
five-year_JJ
survival_NN
rate_NN
of_IN
20_CD
%_NN
._.

According_VBG
to_TO
data_NNS
provided_VBN
by_IN
the_DT
National_NNP
Cancer_NNP
Institute_NNP
,_,
the_DT
median_JJ
age_NN
of_IN
incidence_NN
of_IN
lung_NN
cancer_NN
is_VBZ
70_CD
years_NNS
,_,
and_CC
the_DT
median_JJ
age_NN
of_IN
death_NN
by_IN
lung_NN
cancer_NN
71_CD
years_NNS
._.

Worldwide_NNP
,_,
lung_NN
cancer_NN
is_VBZ
the_DT
most_RBS
common_JJ
cancer_NN
in_IN
terms_NNS
of_IN
both_DT
incidence_NN
and_CC
mortality_NN
with_IN
1.35_CD
million_CD
new_JJ
cases_NNS
per_IN
year_NN
and_CC
1.18_CD
million_CD
deaths_NNS
,_,
with_IN
the_DT
highest_JJS
rates_NNS
in_IN
Europe_NNP
and_CC
North_NNP
America_NNP
._.

The_DT
population_NN
segment_NN
most_RBS
likely_JJ
to_TO
develop_VB
lung_NN
cancer_NN
is_VBZ
over-fifties_NNS
who_WP
have_VBP
a_DT
history_NN
of_IN
smoking_NN
._.

Lung_NNP
cancer_NN
is_VBZ
the_DT
second_JJ
most_RBS
commonly_RB
occurring_VBG
form_NN
of_IN
cancer_NN
in_IN
most_JJS
western_JJ
countries_NNS
,_,
and_CC
it_PRP
is_VBZ
the_DT
leading_VBG
cancer-related_JJ
cause_NN
of_IN
death_NN
._.

Although_IN
the_DT
rate_NN
of_IN
men_NNS
dying_VBG
from_IN
lung_NN
cancer_NN
is_VBZ
declining_VBG
in_IN
western_JJ
countries_NNS
,_,
it_PRP
is_VBZ
actually_RB
increasing_VBG
for_IN
women_NNS
due_JJ
to_TO
the_DT
increased_VBN
takeup_NN
of_IN
smoking_NN
by_IN
this_DT
group_NN
._.

Among_IN
lifetime_NN
non-smokers_NNS
,_,
men_NNS
have_VBP
higher_JJR
age-standardized_JJ
lung_NN
cancer_NN
death_NN
rates_NNS
than_IN
women_NNS
._.

Not_RB
all_DT
cases_NNS
of_IN
lung_NN
cancer_NN
are_VBP
due_JJ
to_TO
smoking_NN
,_,
but_CC
the_DT
role_NN
of_IN
passive_JJ
smoking_NN
is_VBZ
increasingly_RB
being_VBG
recognized_VBN
as_IN
a_DT
risk_NN
factor_NN
for_IN
lung_NN
cancer_NN
,_,
leading_VBG
to_TO
policy_NN
interventions_NNS
to_TO
decrease_VB
undesired_JJ
exposure_NN
of_IN
non-smokers_NNS
to_TO
others_NNS
'_POS
tobacco_NN
smoke_NN
._.

Emissions_NNS
from_IN
automobiles_NNS
,_,
factories_NNS
and_CC
power_NN
plants_NNS
also_RB
pose_VBP
potential_JJ
risks_NNS
._.

Eastern_NNP
Europe_NNP
has_VBZ
the_DT
highest_JJS
lung_NN
cancer_NN
mortality_NN
among_IN
men_NNS
,_,
while_IN
northern_JJ
Europe_NNP
and_CC
the_DT
U.S_NNP
._.

have_VB
the_DT
highest_JJS
mortality_NN
among_IN
women_NNS
._.

Lung_NNP
cancer_NN
incidence_NN
is_VBZ
currently_RB
less_RBR
common_JJ
in_IN
developing_VBG
countries_NNS
._.

With_IN
increased_VBN
smoking_NN
in_IN
developing_VBG
countries_NNS
,_,
the_DT
incidence_NN
is_VBZ
expected_VBN
to_TO
increase_VB
in_IN
the_DT
next_JJ
few_JJ
years_NNS
,_,
notably_RB
in_IN
China_NNP
and_CC
India_NNP
._.

Lung_NNP
cancer_NN
incidence_NN
-LRB-_-LRB-
by_IN
country_NN
-RRB-_-RRB-
has_VBZ
an_DT
inverse_JJ
correlation_NN
with_IN
sunlight_NN
and_CC
UVB_NN
exposure_NN
._.

One_CD
possible_JJ
explanation_NN
is_VBZ
a_DT
preventative_JJ
effect_NN
of_IN
vitamin_NNP
D_NNP
-LRB-_-LRB-
which_WDT
is_VBZ
produced_VBN
in_IN
the_DT
skin_NN
on_IN
exposure_NN
to_TO
sunlight_NN
-RRB-_-RRB-
._.

Lung_NNP
cancer_NN
was_VBD
extremely_RB
rare_JJ
before_IN
the_DT
advent_NN
of_IN
cigarette_NN
smoking_NN
._.

Lung_NNP
cancer_NN
was_VBD
first_RB
recognized_VBN
as_IN
a_DT
distinct_JJ
disease_NN
in_IN
1761_CD
._.

Different_JJ
aspects_NNS
of_IN
lung_NN
cancer_NN
were_VBD
described_VBN
further_RBR
in_IN
1810_CD
._.

Malignant_JJ
lung_NN
tumors_NNS
made_VBD
up_RP
only_RB
1_CD
%_NN
of_IN
all_DT
cancers_NNS
seen_VBN
at_IN
autopsy_NN
in_IN
1878_CD
,_,
but_CC
had_VBD
risen_VBN
to_TO
10_CD
--_:
15_CD
%_NN
by_IN
the_DT
early_JJ
1900s_NNS
._.

Case_NN
reports_NNS
in_IN
the_DT
medical_JJ
literature_NN
numbered_VBD
only_RB
374_CD
worldwide_RB
in_IN
1912_CD
._.

A_DT
review_NN
of_IN
autopsies_NNS
showed_VBD
that_IN
the_DT
incidence_NN
of_IN
lung_NN
cancer_NN
had_VBD
increased_VBN
from_IN
0.3_CD
%_NN
in_IN
1852_CD
to_TO
5.66_CD
%_NN
in_IN
1952_CD
._.

In_IN
Germany_NNP
,_,
in_IN
1929_CD
physician_NN
Fritz_NNP
Lickint_NNP
recognized_VBD
the_DT
link_NN
between_IN
smoking_NN
and_CC
lung_NN
cancer_NN
._.

This_DT
led_VBD
to_TO
an_DT
aggressive_JJ
anti-smoking_JJ
campaign_NN
._.

The_DT
British_JJ
Doctors_NNS
Study_NN
,_,
published_VBN
in_IN
the_DT
1950s_NNS
,_,
was_VBD
the_DT
first_JJ
solid_JJ
epidemiological_NN
evidence_NN
of_IN
the_DT
link_NN
between_IN
lung_NN
cancer_NN
and_CC
smoking_NN
._.

As_IN
a_DT
result_NN
,_,
in_IN
1964_CD
the_DT
Surgeon_NNP
General_NNP
of_IN
the_DT
United_NNP
States_NNPS
recommended_VBD
that_IN
smokers_NNS
should_MD
stop_VB
smoking_NN
._.

The_DT
connection_NN
with_IN
radon_NN
gas_NN
was_VBD
first_RB
recognized_VBN
among_IN
miners_NNS
in_IN
the_DT
Ore_NNP
Mountains_NNPS
near_IN
Schneeberg_NNP
,_,
Saxony_NNP
._.

Silver_NNP
has_VBZ
been_VBN
mined_VBN
there_RB
since_IN
1470_CD
._.

However_RB
these_DT
mines_NNS
are_VBP
rich_JJ
in_IN
uranium_NN
,_,
with_IN
accompanying_VBG
radium_NN
and_CC
radon_NN
gas_NN
._.

Miners_NNS
developed_VBD
a_DT
disproportionate_JJ
amount_NN
of_IN
lung_NN
disease_NN
,_,
eventually_RB
recognized_VBN
as_IN
lung_NN
cancer_NN
in_IN
the_DT
1870s_CD
._.

An_DT
estimated_VBN
75_CD
%_NN
of_IN
former_JJ
miners_NNS
died_VBD
from_IN
lung_NN
cancer_NN
._.

Despite_IN
this_DT
discovery_NN
,_,
mining_NN
continued_VBD
into_IN
the_DT
1950s_NNS
due_JJ
to_TO
the_DT
USSR_NN
's_POS
demand_NN
for_IN
uranium_NN
._.

The_DT
first_JJ
successful_JJ
pneumonectomy_NN
for_IN
lung_NN
cancer_NN
was_VBD
carried_VBN
out_RP
in_IN
1933_CD
._.

Initially_RB
,_,
pneumonectomy_NN
was_VBD
the_DT
surgical_JJ
treatment_NN
of_IN
choice_NN
._.

However_RB
with_IN
improvements_NNS
in_IN
cancer_NN
staging_NN
and_CC
surgical_JJ
techniques_NNS
,_,
lobectomy_NN
with_IN
lymph_NN
node_NN
dissection_NN
has_VBZ
now_RB
become_VBN
the_DT
treatment_NN
of_IN
choice_NN
._.

Palliative_NNP
radiotherapy_RB
has_VBZ
been_VBN
used_VBN
since_IN
the_DT
1940s_NNS
._.

Radical_NNP
radiotherapy_NN
,_,
initially_RB
used_VBN
in_IN
the_DT
1950s_NNS
,_,
was_VBD
an_DT
attempt_NN
to_TO
use_VB
larger_JJR
radiation_NN
doses_NNS
in_IN
patients_NNS
with_IN
relatively_RB
early_JJ
stage_NN
lung_NN
cancer_NN
,_,
but_CC
who_WP
were_VBD
otherwise_RB
unfit_JJ
for_IN
surgery_NN
._.

In_IN
1997_CD
,_,
continuous_JJ
hyperfractionated_JJ
accelerated_VBN
radiotherapy_NN
-LRB-_-LRB-
CHART_NNP
-RRB-_-RRB-
was_VBD
seen_VBN
as_IN
an_DT
improvement_NN
over_IN
conventional_JJ
radical_JJ
radiotherapy_NN
._.

With_IN
small_JJ
cell_NN
lung_NN
carcinoma_NN
,_,
initial_JJ
attempts_NNS
in_IN
the_DT
1960s_NNS
at_IN
surgical_JJ
resection_NN
and_CC
radical_JJ
radiotherapy_NN
were_VBD
unsuccessful_JJ
._.

In_IN
the_DT
1970s_NNS
,_,
successful_JJ
chemotherapy_NN
regimens_NNS
were_VBD
developed_VBN
._.

